Researchers at Johns Hopkins Medicine report that they have uncovered a promising drug target that could allow scientists to increase or decrease the activity of specific brain proteins. The discovery may lead to new treatments for psychiatric conditions such as anxiety and schizophrenia, as well as a neurological disorder that affects movement and balance. The work was supported by funding from the National Institutes of Health.

The proteins at the center of the research are known as delta-type ionotropic glutamate receptors, or GluDs. These proteins are known to play an important role in how neurons communicate with each other. According to the researchers, mutations in GluDs have been linked to psychiatric disorders, including anxiety and schizophrenia. Despite this connection, scientists have struggled for years to understand exactly how these proteins work, making it difficult to design treatments that could regulate their activity.

“This class of protein has long been thought to be sitting dormant in the brain,” says Edward Twomey, Ph.D., assistant professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine. “Our findings indicate they are very much active and offer a potential channel to develop new therapies.”